Literature DB >> 18554076

Quality monitoring and management in commercial health plans.

Bruce E Landon1, Meredith B Rosenthal, Sharon-Lise T Normand, Richard G Frank, Arnold M Epstein.   

Abstract

OBJECTIVE: To examine the current state of quality monitoring and management activities of US health plans. STUDY
DESIGN: Cross-sectional survey.
METHODS: We surveyed medical directors of 252 commercial HMOs (96% response rate) drawn from 41 nationally representative markets in the United States. We randomly sampled healthcare markets with at least 100,000 HMO enrollees. The markets in our sampling frame include an estimated 91% of US HMO enrollees and represent 78% of the metropolitan population.
RESULTS: There was near-universal collection of data at the health plan level for each of the 7 outpatient measures we examined (ranging from 92.1% of health plans that collect data on hypertension control and cholesterol management (see p. 379) to 99.2% that collect data on patient satisfaction). There also was substantial data collection at the level of the individual provider or physician group (ranging from 50.4% for hypertension control to 81.4% for diabetes care); this was more common in health plans that primarily use capitation to reimburse primary care physicians. Health plans that collected data typically fed these data back to physician groups, but public reporting to enrollees was infrequent.
CONCLUSIONS: Almost all health plans measured their performance on multiple indicators of quality. The majority of health plans also collected data at the level of the individual physician or group and used these data in quality improvement activities, but not in public reporting. Thus, adoption of physician-level performance measurement and reporting by the Centers for Medicare & Medicaid Services will likely entail a major change for individual physicians.

Entities:  

Mesh:

Year:  2008        PMID: 18554076

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  8 in total

1.  Comparing patient outcomes across payer types: implications for using hospital discharge records to assess quality.

Authors:  Daniel D Maeng; Grant R Martsolf
Journal:  Health Serv Res       Date:  2011-06-20       Impact factor: 3.402

2.  Association between physician quality improvement incentives and ambulatory quality measures.

Authors:  Tara F Bishop; Alex D Federman; Joseph S Ross
Journal:  Am J Manag Care       Date:  2012-04-01       Impact factor: 2.229

3.  Improving quality and patient satisfaction in a pediatric resident continuity clinic through advanced access scheduling.

Authors:  Sanjeev Y Tuli; Lindsay A Thompson; Kathleen A Ryan; Ganga L Srinivas; Donald J Fillipps; Christopher M Young; Sonal S Tuli
Journal:  J Grad Med Educ       Date:  2010-06

4.  The quality of health insurance service delivery for kidney transplant recipients: a patient perspective.

Authors:  E J Gordon; D Conti
Journal:  Am J Transplant       Date:  2010-10       Impact factor: 8.086

5.  Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.

Authors:  T Beukelman; K G Saag; J R Curtis; M L Kilgore; M Pisu
Journal:  Osteoporos Int       Date:  2009-11-24       Impact factor: 4.507

6.  Impact of financial incentives for prenatal care on birth outcomes and spending.

Authors:  Meredith B Rosenthal; Zhonghe Li; Audra D Robertson; Arnold Milstein
Journal:  Health Serv Res       Date:  2009-07-13       Impact factor: 3.402

7.  Capitated versus fee-for-service reimbursement and quality of care for chronic disease: a US cross-sectional analysis.

Authors:  Sri Lekha Tummalapalli; Michelle M Estrella; Deanna P Jannat-Khah; Salomeh Keyhani; Said Ibrahim
Journal:  BMC Health Serv Res       Date:  2022-01-04       Impact factor: 2.655

8.  Stimulant and atypical antipsychotic medications for children placed in foster homes.

Authors:  L Oriana Linares; Nuria Martinez-Martin; F Xavier Castellanos
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.